As a co-founder of Aspiro Therapeutics, Josef Vagner spearheads the preclinical development of the company’s lead therapeutic candidate, which includes designing, synthesizing, and characterizing potential drug molecules.
Josef is an accomplished scientist with extensive experience in medicinal chemistry and drug discovery. He has over 25 years of experience in the synthesis and structural analysis of de novo ligands for various biological targets, including a recent focus on ligands targeting GPCRs and multivalent ligands. He is instrumental in developing and implementing strategies for candidate optimization, focusing on improving each drug’s potency, selectivity, and pharmacokinetic properties.
Josef’s expertise ensures that Aspiro’s lead candidates are highly effective and well-positioned for further development.